2017 International Congress Archives - Page 53 of 155

Saccadic impairment in patients with Gaucher’s disease type 3

J. Blume, C. Kämpe Björkvall, M. Machaczka, P. Svenningsson (Stockholm, Sweden)
Safe Functional MR Imaging in STN-DBS implanted Parkinson’s disease

M. Saxena, C. McIntyre, B. Walter (Cleveland, OH, USA)
Safety and tolerability of deep brain stimulation in early stage Parkinson’s disease: Five-year follow-up of medication use and adverse events

A. Currie, M. Turchan, L. Heusinkveld, S. Millan, M. Hacker, A. Molinari, C. Gill, T. Davis, P. Konrad, F. Phibbs, P. Hedera, D. Charles (Memphis, TN, USA)
Safety of levodopa-carbidopa intestinal gel treatment in advanced Parkinson’s disease patients receiving ≥ 2000 mg daily dose of levodopa

C. Zadikoff, J. Boyd, S. Dubow, L. Bergmann, W. Robieson, H. Ijacu, J. Benesh (Chicago, IL, USA)
Safety of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson’s disease: Preliminary Results from a Phase III Study

S. Isaacson, R. Hauser, A. Espay, R. Pahwa, D. Truong, E. Pappert, P. Gardzinksi, B. Dzyngel, A. Agro, H. Fernandez (Boca Raton, FL, USA)
Safety of Unilateral and Bilateral DBS implants in ET: Preliminary results from Product Surveillance Registry

M. Schiess, S. Falowski, G. Plotkin, S. Palfi, T. Witt, E. Cuny, T. Theys, K. Martinez, R. Plunkett, Y. Temel, G. Johnson, T. Weaver, J. Krauss, P. Konrad (Houston, TX, USA)
Safinamide improves both motor and non-motor symptoms in fluctuating Parkinson’s Disease patients.

C. Cattaneo (Bresso (Milan), Italy)
Saliva changes and the oral health in Parkinson´s disease

J. Tiigimäe-Saar, T. Tamme, P. Taba (Tartu, Estonia)
Salivary Alpha-Synuclein in Aging

G. Vivacqua, A. Fabbrini, A. Suppa, R. Mancinelli, G. Fabbrini, C. Colosimo, A. Berardelli (Rome, Italy)
Salivary biomarkers for Huntington’s disease (HD)

J. Corey-Bloom, A. Aikin, S. Park, A. Haque, A. Nathan, D. Granger, S. Granger, E. Thomas (La Jolla, CA, USA)
Sample size estimation for clinical trials in de novo Parkinson’s disease (PD): Results from the Parkinson’s Progression Markers Initiative (PPMI) Study

T. Simuni, C. Caspell-Garcia, N. Seedorff, C. Coffey, S. Lasch, B. Mollenhauer, C. Tanner, K. Kieburtz, K. Marek (Chicago, IL, USA)
Saving Veterans Time, Miles, and Money: Cost Analysis of Video Telemedicine Evaluation of Deep Brain Stimulation (DBS) candidacy at the VA

N. Witek, S. Heath, C. Tanner, N. Galifianakis (San Francisco, CA, USA)
Screening of cognitive impairment in Huntington’s disease with the Parkinson’s Disease – Cognitive Rating Scale (PD-CRS)

S. Martinez-Horta, A. Horta-Barba, J. Perez-Perez, J. Pagonabarraga, J. Marin-Lahoz, J. Kulisevsky (Barcelona, Spain)
Screening of GBA and LRRK2 G2019S Mutations in Egyptian Parkinson’s Disease Patients

L. R'Bibo, S. Hamed, H. Houlden, N. Wood (London, United Kingdom)
Secondary Vascular Parkinsonism in Uzbekistan: Hormonal Pathogenetic Effects and Vascular-Immunological Basics.

D. Akramova (Tashkent, Uzbekistan)
Segregation of subjective and objective clinical measures in Parkinson’s disease

K. Markopoulou, R. Frigerio, A. Premkumar, B. Schoneburg, M. Dudek, S. Walters, C. Wang, D. Maraganore (Evanston, IL, USA)
Self Perception of Dysphagia in Parkinson Disease

A. Silbergleit, C. Sidiropoulos, R. Konnai, L. Schultz, A. Kitowski, P. LeWitt (West Bloomfield, MI, USA)
Self-assessed psychological symptoms, fatigue and depersonalization in dystonia

R. Newby, J. Alty, S. Jamieson, S. Smith, P. Kempster (Melbourne, Australia)
Self-awareness of cognitive functions in Parkinson’s disease patients with and without mild cognitive impairment.

M. Hoock, F. Maier, R. Kaur, C. Eggers, L. Timmermann (Cologne, Germany)
Self-rated burden grading of nonmotor symptoms identifies landmarks and subtypes of Parkinson’s disease: first report from a Moscow-Madrid-London collaboration

N. Titova, S. Cankaya, F. Spinnato, E. Katunina, P. Martinez-Martin, M. Qamar, K.R. Chaudhuri (Moscow, Russian Federation)
Semi-automated MRI algorithm using susceptibility weighted imaging for differentiating multiple system atrophy with parkinsonism from Parkinson Disease

W.-W. Lee, H.-J. Kim, C.-H. Sohn, H. Park, B. Jeon (Seoul, Republic of Korea)
Semiquantitative analyses of DAT-SPECT imaging with an automated striatal analysis software in differential diagnosis of neurodegenerative parkinsonism

N. Morimoto, M. Takamiya, M. Morimoto (Takamatsu, Japan)
Sensory modulation of postural control in Huntington’s disease

F. Porciuncula, K. Marder, P. Wasserman, A. Rao (New York, NY, USA)
Sensory trick in a dystonic patient: insights from Magnetoencephalogram

A. Mahajan, A. Zillgitt, S. Bowyer, C. Sidiropoulos (Detroit, MI, USA)
Sensory trick phenomenon in cervical dystonia: a functional MRI study

E. Sarasso, F. Agosta, S. Amadio, C. Butera, F. Bianchi, P. Valsasina, R. Guerriero, G. Comi, R. Gatti, U. Del Carro, M. Filippi (Milan, Italy)
Sentence comprehension in Slovak speaking patients with Parkinson´s disease – preliminary results

A. Kušnírová, J. Marková, Z. Košutzká, M. Egryová, M. Pápayová, P. Valkovič, Z. Cséfalvay (Bratislava, Slovakia)
Serotonergic, Dopaminergic Disruptions and Related Non-Motor Features Throughout the Course of Parkinson’s Disease: A Transversal PET Study

A. Maillet, E. Météreau, E. Favre, E. Lhommée, H. Klinger, D. Le Bars, A. Castrioto, V. Sgambato-Faure, L. Tremblay, E. Broussolle, P. Krack, S. Thobois (Lyon, France)
Serotonin–to–dopamine transporter ratios in Parkinson’s dyskinesias: the longitudinal study

A.-A. Roussakis, N. Lao-Kaim, A. Martin-Bastida, N. Valle-Guzman, M. Politis, T. Foltynie, R. Barker, P. Piccini (London, United Kingdom)
Serum cholesterol levels over time and risk of Parkinson’s disease

V. Rozani, T. Gurevich, N. Giladi, B. El-Ad, J. Tsamir, B. Hemo, C. Peretz (Tel A viv, Israel)
Serum lipid profile in Parkinsons disease patients from Southern Spain

C. Mendez Barrio, D. Macias Garcia, S. Jesus, M.A. Labrador Espinosa, L. Vargas Gonzalez, M. Bernal Escudero, A. Adarmes Gomez, F. Carrillo Garcia, M. Carvallo Cordero, P. Gomez Garr, P. Mir (Seville, Spain)
Serum Mir-30c as a Potential Biomarker to Discriminate MSA from PD Patients: A Pilot Study.

A. Vallelunga, M. Sessa, D. Giovanna, M. Picillo, P. Barone, M.T. Pellecchia (Salerno, Italy)
Serum soluble transferrin receptor levels correlate with the Hoehn & Yahr stage of Parkinson disease progression

P. Costa-Mallen, S.-C. Hu, P. Agarwal (Kenmore, WA, USA)
Serum uric acid levels and freezing of gait in Parkinson’s disease

R. Ou, B. Cao, Q. Wei, Y. Hou, Y. Xu, W. Song, B. Zhao (Chengdu, China)
Serum vitamin B12 levels in patients with Parkinson’s disease and its association with peripheral neuropathy and cognition

R. Kandadai, N. Mathukumali, S.S. Meka, S. Tandra, A. Kohat, M. Kanikannan, R. Borgohain (Hyd, India)
Severity Assessment, Functional Capacity and Balance in Patients with Spinocerebellar Ataxias (SCAs): comparison between types 3 and 10.

F. Germiniani, K. Konno, M. Zonta, A. Guimarães, H. Teive (Curitiba, Brazil)
Sex Differences in Homebound Advanced Parkinson’s Disease Patients

L. Nwabuobi, W. Barbosa, M. Sweeney, S. Oyler, A. Lemen, T. Meisel, A. Di Rocco, J. Chodosh, J. Fleisher (New York, NY, USA)
Sexual Dysfunction in Women with Parkinson’s Disease

A. Hannoun, E. Adams, K. Smith, N. Cohen, A. Deb (Worcester, MA, USA)
Short term effects of bilateral STN DBS on psychiatric profile in Parkinson’s disease

R. Alugolu, M.B. Kesani, B. Ganji, V. Mudumba, R. Mrudula, R. Borgohain, P. Gaddamanugu (Hyderabad, India)
Signal intensity of cerebral gyri in corticobasal degeneration on phase difference enhanced MR images: Comparison with progressive supranuclear palsy and Parkinson’s disease

M. Miyata, S. Kakeda, T. Yoneda, S. Ide, K. Watanabe, J. Moriya, H. Narimatsu, T. Sato, K. Okada, H. Adachi, Y. Korogi (Kitakyushu, Japan)
Skin nerve phosphorylated α-synuclein deposits in idiopathic REM sleep behavior disorder.

E. Antelmi, V. Donadio, G. Plazzi, R. Liguori (Bologna, Italy)
Sleep architecture in Parkinson´s disease and Parkinson’s disease associated dementia

L. Sousa, I. Laranjinha, J. Lopes, J. Ramalheira, A.M. da Silva, A.B. Lima, M. Magalhães (Porto, Portugal)
Sleep disturbance may alter white matter and resting state functional connectivities in Parkinson’s disease

S.J. Chung, Y.-H. Choi, H. Kwon, Y.-H. Park, H.J. Yun, H.S. Yoo, Y.H. Sohn, J.-M. Lee, P.H. Lee (Seoul, Republic of Korea)
Sleep quality in patients with advanced Parkinson’s disease treated with levodopa/carbidopa intestinal gel infusion

O. De Fabregues, A. Ferré, O. Romero, J. Dot, M. Abu-Suboh, M. Quintana, J.R. Armengol, J. Alvarez-Sabin (Barcelona, Spain)
Sleepiness and depression in Korean patients with Parkinson’s disease treated with ropinirole and levodopa

S.Y. Kang, H.-S. Ryu, M.-K. Sunwoo, S.-J. Kim, J.-S. Baik, M.-Y. Park, H.-E. Park, J.-S. Kim, K.-Y. Kwon, S.-B. Koh, Y.-E. Kim, M.-K. Lee, J.-M. Kim, S.J. Chung, Y.-H. Sohn (Hwaseong, Republic of Korea)
Slow Release Fixed Dose Combination of Low Doses Pramipexole and Rasagiline (P2B001) for the Treatment of Early Parkinson’s Disease (PD).

C. Olanow, K. Kieburtz, N. Livnah (New York, NY, USA)
SNCA multiplication consortium: Clinicogenetic analysis of SNCA multiplication probands and families.

A. Book, M. Farrer, T. Candido, I. Guella, D. Evans, E. Gustavsson (Vancouver, BC, Canada)
Social hindrances for diagnosing Huntington’s disease

A. Alboudi, P. Sarathchandran, A.B. Almadani (Dubai, United Arab Emirates)
Social importance of care and rehabilitation in restoring of psycho-emotional and movement deficits in Parkinsonism.

M. Sanoeva, M. Gulova, M. Avezova, N. Mansurova (Bukhara, Uzbekistan)
Somatosensory Mismatch Negativity is abnormal in Cervical Dystonia.

J.-C. CHEN, M. Edwards, J. Rothwell, A. Macerollo (Taichung city, Taiwan)
Some clincal features of movement disorders after cerebral anoxia.

B. Tserensodnom (Ulaanbaatar, Mongolia)
Somnolence as untoward stimulation effect in subthalamic deep brain stimulation (STN DBS) for Parkinson’s disease (PD)

F. Danisi, C. Miller (Poughkeepsie, NY, USA)
Spanish Primary Familial Brain Calcification caused by SLC20A2 mutation

N. Caballol, E. Peral, M. Balague, E. Moral, L. Vila, G. Celma, L. Vives, I. Royo, A. Ferran, A. Torrents, E. Gean, A. Ávila (Sant Joan Despí, Spain)
Spasmodic Dysphonia in Hereditary Spastic Paraplegia Type 7

D. Hall, N. Stong, N. Lippa, M. Pitman, S. Pullman, O. Levy (New York, NY, USA)
Spastic paraplegia type 4: a novel SPAST splice site donor mutation and expansion of the phenotype variability

A. Orlacchio, C. Montecchiani, R. Miyamoto, M. Mearini, L. D'Onofrio, M. Miele, F. Gaudiello, Y. Izumi, C. Caltagirone, R. Kaji, T. Kawarai (Rome, Italy)
Specific Bdnf variants are associated with suboptimal response to levodopa but not to other dopaminergic medications or deep brain stimulation in Parkinson’s disease

C. Sortwell, P. Auinger, J. Goudreau, B. Pickut, B. Berryhill, M. Hacker, D. [email protected], J. Lipton, A. Cole-Strauss, J. Elm, D. Fischer (Grand Rapids, MI, USA)
Specific Metabolic Brain Networks Associated with Parkinsonian and Cerebellar Variants of Multiple System Atrophy

P. Wu, S. Peng, J. Wang, J. Wu, C. Jiang, J. Ge, D. Eidelberg, Y. Ma, C. Zuo (Shanghai, China)
SPECT imaging of striatal DAT availability in Parkinson’s: changes over time and relevance to dyskinesias

A.-A. Roussakis, D. Towey, P. Piccini (London, United Kingdom)
Spectrum of non-motor symptoms in essential tremor in a Tunisian population

M. Ben Djebara, I. Kacem, S. Mrabet, Y. Sidhom, B. Saguem, A. Nasri, A. Gargouri, R. Gouider (Manouba, Tunisia)
Speech and voice response to levodopa in late-stage Parkinson’s Disease patients: report from an acute levodopa challenge

M. Fabbri, I. Guimarães, M. Coelho, R. Cardoso, L. Guedes, M. Rosa, C. Godinho, A. Antonini, J. Ferreira (Lisbon, Portugal)
Speech difficulties are linked to striatal dopaminergic deficits and cognitive decline in early de novo patients with Parkinson’s disease

S. Polychronis, F. Niccolini, G. Pagano, M. Politis (London, United Kingdom)
Speech Markers Estimate Motor Severity and Global Cognition in Parkinson’s Disease

K. Smith, T. Quatieri, J. Williamson (Worcester, MA, USA)
Spg 11 gene mutation associated autosomal recessive hereditary spastic paraplegia presenting with partially levodopa responsive parkinsonism, stereotypy and cognitive decline.

S. Desai, S. Singh, V. Patel, J. Sheth (Anand, India)
SPG7 related spastic ataxia differs according to the presence of the A510V variant

G. Coarelli, M.-L. Monin, C. Ewenczyk, B. Fontaine, J.-P. Azulay, P. Calvas, E. Ollagnon-Roman, G. Sole, G. Banneau, A. Brice, G. Stevanin, C. Duyckaerts, A. Durr (Paris, France)
SPG7-related ataxia in the Irish National Ataxia Clinic cohort: case series

P. Bogdanova-Mihaylova, S. Murphy, R. Walsh (Dublin, Ireland)
Spinal cord stimulation as therapeutic option in gait disorder in Parkinson disease.

H. Cécile, D'H. Vincent, B.M. MALEK, p.-k. nathalie, t. Jean-Batiste, Z. MARC, B. Jean-Philippe (PARIS, France)
Spinal cord stimulation reduces freezing of gait and improves gait in advanced Parkinson’s disease

O. Samotus, N. Kumar, S. Memar, M. Jog (London, ON, Canada)
Spinocerebellar Ataxia type 11 in a Hispanic Kindred

D. Machado, J.A. deMarcaida (Vernon, CT, USA)
Spinocerebellar ataxia type-17: An Indian Scenario

S. Shakya, P. Negi, A. Garg, M. Prasad, M. Faruq, A. Srivastava (New Delhi, India)
Spiral Analysis is a Promising Biomarker in LRRK2 G2019S carriers

R. Ortega, M. Pullman, A. Glickman, I. Perera, M. San Luciano, A. Mirelman, C. Pont-Sunyer, N. Giladi, E. Tolosa, Q. Yu, S. Bressman, S. Pullman, R. Saunders-Pullman (New York, NY, USA)
Sports or no sports – is that the question in PD?

M. Strothjohann, P. Kostopoulos, F. Weber (Bad Camberg, Germany)
Stabile cognitive profile one year after subthalamic nucleus deep brain stimulation in patients with advanced Parkinson’s disease

T. Remšak, A. Bujisić, S. Šešok, S. Brezovar, A. Pražnikar, M. Kramberger, D. Georgiev, D. Flisar, K. Boetzel, J. Mehrkens, M. Benedičič, Z. Pirtošek, M. Trošt (Ljubljana, Slovenia)
Status dystonicus treated by Deep Brain Stimulation in Niemann Pick type C

V. Gonzalez, L. Cif, X. Ayrignac, F. Cyprien, E. Nerrant, E. Sanrey, E. Chan seng, M. Koenig, P. Coubes (Montpellier, France)
Steroid-responsive encephalopathy with associated thyroiditis (SREAT) presenting with pure cerebellar ataxia

P. Termsarasab, Y. Pitakpatapee, S. Frucht, P. Srivanitchapoom (Bangkok, Thailand)
Stiff-limb syndrome with cerebellar features and atypical EMG findings responds to IVIG

S. Rametta, G. Robinson, N. Hellmers, N. Jacoby, H. Sarva (Brooklyn, NY, USA)
Stimulation in the nucleus entopeduncularis affects neuronal activity in the nucleus accumbens and medial prefrontal cortex after apomorphine-induced deficient prepulse inhibition in rats

K. Schwabe, J. Krauss, M. Alam (Hannover, Germany)
STN DBS can temporarily improve balance disorders in Parkinson’s disease (PD) patients.

S. Szlufik, M. Kloda, I. Potrzebowska, K. Gregier, A. Friedman, A. Przybyszewski, J. Dutkiewicz, P. Habela, T. Mandat, D. Bialoszewski, D. Koziorowski (Warsaw, Poland)
Striatal Cholinergic Neurons in Cervical Dystonia

K. Mente, N. Edwards, D. Pratt, D. Iacono, D. Urbano, A. Ray-Chaudhury, M. Hallett (Bethesda, MD, USA)
Striatal dopamine transporter abnormalities in pure autonomic failure and speculation about the relationship with Lewy bodies

M. Yogo, M. Morita, M. Suzuki (Tokyo, Japan)
Striato-cortical connections in Parkinson’s and Alzheimer’s diseases: relation to cognition

I. Rektorova, L. Anderkova, M. Barton (Brno, Czech Republic)
Structural and Functional Correlates of Anxiety in Parkinson’s disease.

F. Růžička, T. Ballarini, O. Bezdíček, J. Roth, T. Sieger, J. Vymazal, E. Růžička, K. Mueller, R. Jech (Prague, Czech Republic)
Structural brain abnormalities associated with preclinical cognitive impairment in Idiopathic Parkinson’s Disease.

C. Lambert, O. Williams, L. Ricciardi, F. Morgante, T. Barrick, M. Edwards (London, United Kingdom)
Structural brain changes in patients with Multi System Atrophy: A VBM and DTI based study.

J. Saini, P. Pal, L. George, S. Dash (Bangalore, India)
Study Design for a Multi-Modal Approach to Understanding Parkinson’s Disease: The Personalized Parkinson Project

W. Marks, Jr., L. Evers, M. Faber, M. Verbeek, N. de Vries, B. Bloem (South San Francisco, CA, USA)
Study Design of an Efficacy and Safety Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of APL-130277 in the Treatment of OFF Episodes (CTH-300)

C.W. Olanow, E. Pappert, P. Gardzinski, B. Dzyngel, A. Agro (New York, NY, USA)
Study in Parkinson’s Disease of Exercise (SPARX): A Randomized, Controlled Futility Trial

D. Corcos, C. Moore, W. Kohrt, D. Hall, A. Delitto, C. Comella, D. Josbeno, C. Christiansen, B. Berman, B. Kluger, E. Melanson, S. Jain, J. Robichaud, C. Poon, M. Schenkman (Chicago, IL, USA)
Study of an early wellness program in Parkinson’s disease: impact on quality of life and early intervention guidance

B. Page, H. Shill (Phoenix, AZ, USA)
Study of neuroprotective effects of Ginsenside Rg3 , the prototypal epigenetic Sirtuin-1 activator, in targeting microglia activation and neurotrophic factor (NF) neural plasticity in MPTP model of Parkinson’s disease (PD)

H. Raheb, J. Hou, S. Chiu (London, ON, Canada)
Subcortical involvement in body and mental action processing: an electrophysiological registration study

M. De Letter, P. Santens, D. Van Roost, G. Strobbe, P. Van Mierlo, A. Aerts, A. Bruggeman, K. De Keyser (Ghent, Belgium)
Subcortical involvement in phonological input processing: an electrophysiological registration study

A. Bruggeman, K. De Keyser, A. Aerts, P. Van Mierlo, G. Strobbe, D. Van Roost, P. Santens, M. De Letter (Ghent, Belgium)
Subcortical local shape volume analysis of progressive mild cognitive impairment in Parkinson`s disease

S.J. Chung, J.-H. Shin, K.h. Cho, Y. Lee, H.S. Yoo, S.J. Chung, Y.H. Sohn, J.-K. Seong, P.H. Lee (Seoul, Republic of Korea)
Subjective cognitive complaints in Parkinson’s disease patients: what should we value ?

R. Barbosa, M. Mendonça, T. Lampreia, R. Miguel, A. Caetano, P. Bugalho (Lisbon, Portugal)
Subjective cognitive decline reflects recent cognitive change in non-demented patients with Parkinson’s disease

J.Y. Hong, Y. Lee, M. Sunwoo, Y. Sohn, P.H. Lee (Wonju, Republic of Korea)
Subjective visual vertical in patients with early Parkinson’s disease

H.S. Kim, H. Lee, S. Chu (Kyunggi-do, Republic of Korea)
Substantia nigra area evaluated by neuromelanin-sensitive MRI as an imaging biomarker of disease progression in Parkinson’s disease

M. Fabbri, S. Reimão, M. Carbalho, R. Nunes, D. Abreu, L. Guedes, R. Bouça, P. Lobo, C. Godinho, M. Coelho, N. Gonçalves, M. Rosa, A. Antonini, J. Ferreira (Lisbon, Portugal)
Substantia nigra hyperechogenicity in male methamphetamine users

G. Todd, V. Pearson-Dennett, B. Collie, J. White (Adelaide, Australia)
Substantial psychiatric symptoms, sleep disturbances and reduced quality of life in well-treated adult patients with GTP-cyclohydrolase deficient dopa-responsive dystonia

A. Kuiper, E. Timmers, M. Smit, T. De Koning, M. Tijssen (Groningen, Netherlands)
Subthalamic Nucleus Deep Brain Stimulation in Early Stage Parkinson’s Disease Reduces the Risk of Polypharmacy: Five-Year Analysis

M. Hacker, M. Turchan, A. Currie, L. Heusinkveld, S. Millan, T. Davis, F. Phibbs, P. Hedera, P. Konrad, D. Charles (Nashville, TN, USA)
Subthalamic nucleus local field potential activity during the sleep-wake cycle

A. Tekriwal, J. Thompson, A. Abosch (Aurora, CO, USA)
Successful deep brain stimulation treatment of incapacitating tremor resulting from bilateral thalamic infarcts complicating surgery for Arnold Chiari malformation/syringomyelia.

S. Alusi, M. Bonello, K. Das, L. Lowry, P. Eldridge (Liverpool, United Kingdom)
Successful passive monitoring of early-stage Parkinson’s disease patient mobility in Phase I RG7935/PRX002 clinical trial with smartphone sensors

F. Lipsmeier, I. Fernandez Garcia, D. Wolf, T. Kilchenmann, A. Scotland, J. Schjodt-Eriksen, W.-Y. Cheng, J. Siebourg-Polster, L. Jin, J. Soto, L. Verselis, M. Martin Facklam, F. Boess, M. Koller, M. Grundman, M. Little, A. Monsch, R. Postuma, A. Gosh, T. Kremer, K. Taylor, C. Czech, C. Gossens, M. Lindemann (Basel, Switzerland)
Sudden onset of parkinsonism in a case of dural arteriovenous fistula

H. Kawasaki, T. Yamamoto, A. Miyake, K. Ikeda, T. Mistuhuji, Y. Ito, K. Takahashi, N. Tamura, N. Araki (Moroyama, Japan)
Suicidality in Parkinson’s Disease: A Case Control Study

M. Akbostanci, E. Bayram, D. Sayar, T. Ayidaga (Ankara, Turkey)
Suicide in Parkinson disease

W. Li, H. Seah, L. Ng, Y. Tay, L. Au, L. Tan (Singapore, Singapore)
Swallowing difficulties and Parkinson’s disease

S. Polychronis, G. Dervenoulas, G. Pagano, F. Niccolini, M. Politis (London, United Kingdom)
SweetSpot of antidystonic effect in pallidal neurostimulation: a European multicentre imaging study

M. Reich, L. Lange, J. Roothans, A. Horn, F. Wodarg, J. Runge, M. Aström, F. Steigerwald, K. Witt, R. Nickl, P. Plettig, M. Wittstock, V. Coenen, P. Mahlknecht, W. Poewe, W. Eisner, C. Matthies, A. Kühn, J. Krauss, G. Deuschl*, J. Volkmann* (Wuerzburg, Germany)
Syndenham’s chorea in Senegalese children: A case series

F.S. NGOUNGOURE HALIMA, M. NDIAYE, A.D. SOW, B. SECK, M.M. NDIAYE (Dakar, Senegal)
Synthesis and pharmacological evaluation of 16-aryldieno steroids as anti-parkinsonian agents in LPS induced Neuroinflammation Model of Rat

R. Bansal, R. Singh (Chandigarh, India)
Systematic Evaluation of Major and Minor Psychotic Symptoms in Parkinson’s Disease

C. Kulick, K. Montgomery, M. Nirenberg (New York, NY, USA)